Sustainability Report 2025‑26 Highlights

Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) issued its Sustainability Report for FY 2025‑26 on 26 August 2026, outlining progress across environmental, social and governance (ESG) pillars.

Environmental Performance

  • Scope 1 and Scope 2 greenhouse‑gas emissions fell 22.6 % compared with the FY 2022 baseline, representing the lowest‑ever levels recorded by the company under its Science‑Based Targets initiative (SBTi)‑approved decarbonisation roadmap.
  • Renewable energy accounted for 41 % of total energy consumption across all operations.
  • Water stewardship saw 2.63 lakh kilolitres of freshwater recycled or reused.
  • Waste management improved, with 65 % of total waste diverted for recycling.

Quality, Regulatory and Operational Excellence

  • The firm completed 38 regulatory inspections during the year, including three United States Food and Drug Administration (USFDA) inspections that resulted in zero Official Action Indicated (OAI) observations.
  • 209 customer audits were carried out, reinforcing quality and compliance across the global manufacturing network.
  • Digital transformation progressed through the rollout of Catalyst NxGen, implementation of SAP S/4HANA, and expansion of digital quality systems.

Capital Investment

  • Piramal announced a US$90 million capital expenditure programme to expand advanced therapeutics capabilities at its Lexington and Riverview facilities.

Governance and People

  • No data‑breach incidents or corruption cases were recorded during the reporting period.
  • ESG training achieved 100 % completion across all employees, and Code of Conduct training also reached 100 % completion.
  • Women comprised 30 % of the Board of Directors and 20.1 % of the global workforce.
  • 38 % of critical suppliers were assessed against the company’s sustainability criteria as part of its responsible‑supply‑chain programme.

Community Impact

  • CSR spending amounted to ₹8.98 crore, reaching nearly 1.8 million beneficiaries across 112 aspirational districts through health‑care and education initiatives.

Leadership Commentary

  • Chairperson Nandini Piramal stated that sustainability is a catalyst for innovation and resilience, emphasizing continued investment in cleaner operations, digital capabilities, people development and value‑chain partnerships.

Corporate Structure and Oversight

  • The sustainability agenda is governed by the Sustainability and Risk Management Committee and aligns with GRI standards, SASB and UNGC frameworks.
  • Piramal Pharma operates 17 global development and manufacturing facilities, serves over 100 countries, and includes subsidiaries Piramal Pharma Solutions, Piramal Critical Care, Piramal Consumer Healthcare, and the joint‑venture Abbvie Therapeutics India Private Limited, a leader in ophthalmology in India.

Contacts

  • Investor Relations & Enterprise Risk Management: Gagan Borana (gagan.borana@piramal.com)
  • Media: Madiha Vahid, Lead – Branding & Communications (madiha.vahid@piramal.com)